Herceptin | eHealth News

Neratinib-paclitaxel is no better than trastuzumab-paclitaxel for progression-free survival in recurrent and/or metastatic ERBB2-positive breast cancer

Neratinib Not Superior to Trastuzumab in ERBB2-Breast CA

HealthDay.com - Apr 15, 2016

Neratinib-paclitaxel doesn't improve progression-free survival versus trastuzumab-paclitaxel

The drug combination of lapatinib (Tykerb) and trastuzumab (Herceptin) induces tumor regression or disappearance in 25 percent of human epidermal growth factor receptor 2 (HER2)-positive cancers in 11 days

Lapatinib + Trastuzumab May Rapidly Shrink Breast Tumors

HealthDay.com - Mar 10, 2016

Researchers say combo therapy works well for about one in four women with HER2+ breast cancer

Archives